Feasibility of using stereotactic body radiation therapy for unresectable soft tissue tumors of the trunk.

Eun Kyung Paik,Sung-Ho Jin,Mi-Sook Kim,Chul-Koo Cho,Dong Han Lee,Hyung Jun Yoo,Dae Geun Jeon,Won Il Jang,Young-Seok Seo

doi:10.18632/oncotarget.25539

Abstract

PurposeTo evaluate the feasibility of stereotactic body radiation therapy (SBRT) for unresectable soft tissue tumors of the trunk.Materials and MethodsBetween January 2002 and December 2008, 23 patients with 36 lesions of soft tissue tumors, which were located in the trunk and not suitable for resection, underwent SBRT. Among the 36 lesions, 31 were malignant and 5 were benign. The median tumor volume was 24 cm3 (range, 2.6–213 cm3). SBRT doses ranged from 20 to 48 Gy in 1–5 fractions.ResultsWith a median follow-up of 73 months, the overall survival (OS) and local control (LC) rates at 5 years were 39% and 52%, respectively. For malignant tumors, the OS and LC rates at 5 years were 28% and 47%, respectively. For benign tumors, the OS and LC rates at 5 years were 80% and 100%, respectively. There was no acute toxicity of grade ≥3. One case of grade 3 late skin toxicity was reported 10 months after SBRT.ConclusionSBRT may be an effective and safe treatment modality for the local control of unresectable soft tissue tumors of the trunk including tumors of a benign nature.

Highlights

Soft tissue sarcomas (STSs) are rare tumors arising from connective tissues that can occur in any anatomical site
The treatment outcomes of stereotactic body radiation therapy (SBRT) to 23 patients with 36 lesions of unresectable soft tissue tumors located in the trunk were analyzed
Tumor characteristics of a benign or malignant nature had a significant impact on overall survival (OS) (P = 0.033), and no significant prognostic factor was associated with local control (LC)

Summary

Introduction

Soft tissue sarcomas (STSs) are rare tumors arising from connective tissues that can occur in any anatomical site. They represent about 1% of cancers diagnosed in the US with an annual incidence of about 12,000 cases [1]. The aim of the treatment of STS is to achieve complete eradication of the tumor with optimal function preservation and minimal treatment-related toxicities. The cumulative probability of local recurrence at 5 years in extremity STS, as reported in large series, remains as high as 20% [3,4,5,6]

Objectives

Methods

Results

Conclusion